<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142646</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT03142646</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells</brief_title>
  <acronym>IM19CAR-T</acronym>
  <official_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and
      determine the MTD,LTD and the best dosage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>IM19 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T</intervention_name>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>fludarabine，cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CD19+ leukemia, meeting the following criteria

               -  At least 2 prior combination chemotherapy regimens (not including single agent
                  monoclonal antibody (Rituximab) therapy)

               -  Less than 1 year between last chemotherapy and progression

               -  Not eligible or appropriate for allo-HSCT

          -  To be aged 4 to 65 years

          -  Estimated survival of ≥ 6 months, but ≤ 2 years

          -  ECOG score ≤2

          -  Relapse after auto-HSCT

          -  Women of childbearing potential must have a urine pregnancy test taken and proven
             negative prior to the treatment. All patients agree to use reliable methods of
             contraception during the trial period and until follow-up for the last time.

          -  Voluntary participation in the clinical trials and sign the informed consent.

        Exclusion Criteria:

          -  History of epilepsy or other CNS disease

          -  Patients have GVHD, which needs treatment with immunosuppressive agents

          -  Patients with prolonged QT interval or severe heart disease

          -  Patients in pregnancy or breast-feeding period

          -  Uncontrolled active infection

          -  Active hepatitis B or hepatitis C infection

          -  Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
             exclusionary

          -  Previously treatment with any gene therapy products

          -  Feasibility assessment during screening demonstrates &lt;30% transduction of target
             lymphocytes, or insufficient expansion (&lt;5-fold) in response to CD3/CD28 costimulation

          -  ALT /AST&gt;3 x normal value; Creatinine&gt; 2.5 mg/dl; Bilirubin &gt;2.0 mg/dl

          -  Any uncontrolled medical disorders that the researchers consider are not eligible to
             participate the clinical trial

          -  HIV infection

          -  Any situation that would increase dangerousness of subjects or disturb the outcome of
             the clinical study according to the researcher's evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hui liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-an Lu, Dr.</last_name>
    <phone>86-189-1157-6946</phone>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hui liu, MD</last_name>
    <phone>86-15801390058</phone>
    <email>espinas@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui liu, md</last_name>
      <phone>15801390058</phone>
      <email>espinas@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital (PKUPH)</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Huang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaojun Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

